IceCure Medical (ICCM) announced the promotion of Shay Levav to COO, as the company anticipates accelerating commercial momentum following ProSense’s marketing authorization from the U.S. FDA for low risk breast cancer in October 2025. Levav will continue to lead the company’s Regulatory Affairs, Quality Assurance, and Clinical Affairs, under his new role, that he has overseen since 2020.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s Cryoablation System Shows Promising Results in Lung Cancer Treatment
- IceCure Medical Announces Termination of VP of Operations
- Buy Rating for Icecure Medical: FDA Approval and Strategic Initiatives Drive Growth Potential
- IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright
- IceCure Medical’s ProSense® Receives FDA Approval for Breast Cancer Treatment